Esperion Therapeutics (ESPR) Research & Development (2018 - 2025)
Historic Research & Development for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $14.1 million.
- Esperion Therapeutics' Research & Development rose 3591.42% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 1528.22%. This contributed to the annual value of $46.2 million for FY2024, which is 4630.17% down from last year.
- Esperion Therapeutics' Research & Development amounted to $14.1 million in Q3 2025, which was up 3591.42% from $7.2 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Research & Development ranged from a high of $33.0 million in Q4 2022 and a low of $7.2 million during Q2 2025
- Over the past 5 years, Esperion Therapeutics' median Research & Development value was $22.1 million (recorded in 2023), while the average stood at $20.6 million.
- In the last 5 years, Esperion Therapeutics' Research & Development crashed by 5728.94% in 2024 and then skyrocketed by 3591.42% in 2025.
- Esperion Therapeutics' Research & Development (Quarter) stood at $27.6 million in 2021, then rose by 19.62% to $33.0 million in 2022, then tumbled by 46.29% to $17.7 million in 2023, then tumbled by 38.13% to $11.0 million in 2024, then rose by 28.73% to $14.1 million in 2025.
- Its Research & Development was $14.1 million in Q3 2025, compared to $7.2 million in Q2 2025 and $12.6 million in Q1 2025.